Abstract The 117mSn(4+)DTPA has been shown to have high uptake in cortical bone with negligible soft-tissue deposition. The long half-life (14 d) of 117mSn and its emission of abundant short-range Auger and conversion electrons, make 117mSn(4+)DTPA an attractive therapeutic agent for bone tumors. The necessary nuclear data for production of clinical quantities of 117mSn using Sb(p,2pxn) reactions at BLIP was obtained. The excitation functions for 121Sb(p,2p3n) and 123Sb(p,2p5n) reactions in the regions of 43 ≤Ep≤60 MeV were measured and compared with predicted values obtained from semi-empirical formulae given by Silberberg and Tsao. 117mSn is routinely produced at ORNL by thermal neutron activation of 116Sn. We have investigated the possibility of improving the specific activity of the reactor-produced 117mSn by irradiating enriched 116Sn and 117Sn in the core of the HFBR. Our results indicate that, due to a strong absorption resonance at En110 eV, better specific activity for reactor-produced 117mSn can...
[1]
L. Mausner,et al.
The Production of Spallation Radionuclides for Medical Applications at BLIP
,
1983,
IEEE Transactions on Nuclear Science.
[2]
S. K. Banerji,et al.
Cobalt(II) and nickel(II) complexes of some 1-substituted-3-(2-pyridyl)-2-thioureas
,
1976
.
[3]
H. Seidler.
IAEA: HANDBOOK ON NUCLEAR ACTIVATION CROSS‐SECTIONS. IAEA Technical Report Series STI/DOC/10/156, 558 Seiten, Wien 1974. Preis: 26,00 $
,
1975
.
[4]
R. Silberberg,et al.
Partial Cross-Sections in High-Energy Nuclear Reactions, and Astrophysical Applications. I. Targets With z <= 28.
,
1973
.